Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03991793
Other study ID # PI19/070
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date June 20, 2019
Est. completion date December 31, 2020

Study information

Verified date June 2019
Source Instituto de Investigación Sanitaria Aragón
Contact José R Paño-Pardo, MD
Phone +34 976 765700
Email jrpanno@salud.aragon.es
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: Survival in Granzyme A gene (gzmA) knocked-out mice was significantly longer than in wild-type mice in a murine peritonitis model (cecal ligation puncture).

Hypothesis: GZM A has a pathogenic role in sepsis in humans and gzmA polymorphisms can help to predict the risk of sepsis among patients with systemic infections (E. coli bacteremic urinary tract infections).

Objectives:

1. To assess the correlation between GZM A serum levels and systemic inflammatory response in a human model of infection/sepsis (E. coli bacteremic UTI)

2. To characterize gzmA polymorphisms among patients with E. coli bacteremic UTI

3. To determine GZM A serum kinetics among patients with E. coli bacteremic UTI

4. To characterize E. coli strains causing bacteremic UTI: antimicrobial phenotype and virulence factors ("virulome").

Methods:

- Design and setting: Prospective nested case-control study

- Study population: consecutive adult patients with bacteremic urinary tract infections (UTIs) caused by E. coli

- Exclusion criteria: Patients with conditions that significantly compromise immune status or patients exposed to urologic procedures

- Estimated sample size: 50 patients with a sepsis/ non sepsis 1:1 ratio. Septic and non septic patients will be matched on gender, age (+/- 10 years), comorbidity (Charlson score +/-1), time symptom onset to blood culture (+/- 24h)

- Measurements: GZM A serum levels will be determined on day 0, day 2-3, day 30. GZM A kinetics, gzmA polymorphisms (whole exome sequencing).Whole genome sequencing of E. coli isolates retrieved from blood cultures will be performed.

- Analysis: Association between GZM A levels and gzmA polymorphisms and sepsis will be analyzed adjusting for patient, infection and microorganism-related factors (multivariate analysis).


Description:

1. Research hypothesis

The research team has explored the role of GZM A

1. Conceptual hypothesis:

- Granzyme A is a pathogenic sepsis mediator.

- Granzyme A gene polymorphisms determine the serum concentration of GZM A in patients with systemic infections.

- Granzyme A gene polymorphisms determine the risk of sepsis among patients with systemic infections.

2. Operational hypothesis:

- Among patients with bacteremic (E. coli) urinary tract infections (UTIs), GZM A levels are significantly higher in those patients who develop sepsis as compared with those who do not develop sepsis.

- There are significant differences in the GZM A gene polymorphism profile of patients with bacteremic (E. coli) UTIs who develop sepsis as compared with those who do not develop sepsis.

2. Aims and objectives

- Aims

1. To assess the pathogenic role of GZM A in sepsis in patients with bacteremic (E. coli) UTIs.

2. To explore the capability of GZM A polymorphisms to anticipate the risk of developing sepsis in patients with bacteremic (E. coli) UTIs.

3. To evaluate the potential usefulness of GZM A as a diagnostic biomarker of sepsis in patients with bacteremic (E. coli) UTIs.

4. To characterize E. coli "virulome" among circulating uropathogenic strains.

- Objectives

1. To evaluate the correlation between serum levels of GZM A and systemic inflammatory response in patients with bacteremic (E. coli) UTIs.

2. To characterize GZM A gene polymorphisms among patients with bacteremic (E. coli) UTIs

3. To assess GZM A serum kinetics among patients with bacteremic (E. coli) UTIs

4. To phenotypically and molecularly characterize E. coli strains causing bacteremic UTIs, including their virulence factors ("virulome").

3. Expected outcomes.

- Characterization of the pathogenic role of GZM A in sepsis in patients with systemic infections

- Characterization of GZM A as a sepsis biomarker in a human model of infection-sepsis.

- Phenotypical and molecular characterization of uropathogenic E. coli causing bloodstream infections.

4. Methods

4.1. Design and project scope

- Prospective, exploratory nested case-control study to be conducted at one academic hospital (Hospital Clínico Universitario Lozano Blesa) affiliated with the Instituto de Investigación Sanitaria Aragón (IIS Aragón).

4.2. Study period: June 2019 - December 2020.

4.3. Patients and sample size

Inclusion criteria (To meet all):

- Age >= 18 years old.

- E. coli bloodstream infection

- Urinary source. Urinary source should be considered if (any) of the following:

1. Urinary source is clinically suspected and both E. coli isolates (in blood and in urine culture) share the same phenotype (antibiogram).

2. Urinary source/origin is clinically suspected, and the urine culture is negative, but the patient had received at least one dose of any systemic antibiotic with antimicrobial activity against the E. coli strain causing the BSI before blood cultures were obtained.

3. Both isolates (in blood and in urine culture) share the same phenotype (antibiogram) and there is no alternative source.

Exclusion criteria:

1. Use of systemic antibiotics for >48h in the two months preeeding the episode.

2. Immunocompromised hosts - Patients receiving systemic steroid use (>10 mg prednisone/day during 10 or more days in the previous 2 months).

- Patients receiving biological therapy (previous 2 months).

- Active solid or hematological cancer.

- HIV +.

- Neutropenia < 500 PMN/microl.

3. Basal urinary tract abnormalities or locally modified vesical microbiome (any):

- Ureteroileostomy, ureterosigmoidostomy, ureterostomy (Bricker) or nephrostomy.

- Indwelling urinary catheter (in the last two months)

- Urological surgery (in the last two months).

- Intravesical chemotherapy (in the last two months).

- Intravesical BCG instillation (in the last two months).

Potential candidates will be detected daily by the microbiologists on the research team. Inclusion criteria will be verified in the multidisciplinary meeting that antimicrobial stewardship teams (AST) conduct on a daily basis at the participating hospital.

Estimated size of the study population. Matching:

- 50 patients with a sepsis/ non sepsis 1:1 ratio will be included.

- Septic and non-septic patients will be matched on gender, age (+/- 10 years), comorbidity (Charlson score +/-1), time symptom onset to blood culture (+/- 24h)

4.4. Definitions

Cases (sepsis / septic shock):

- Sepsis or shock septic are defined as life-threatening organ dysfunction caused by a dysregulated host response to infection according to the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference.

Controls:

- Absence of sepsis or septic shock according to the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference.

4.5. Variables

4.5.1. Patient-related variables:

- Demographical: gender, age.

- Comorbidity: Modified Charlson Index

- Baseline serum creatinine.

4.5.2. Infection-related variables. - Time from the onset of symptoms to the start of antimicrobial treatment.

- Time from the onset of symptoms to the start of appropriate antimicrobial treatment.

- Time form the onset of symptoms to the surgical therapy (if needed).

- Clinical severity at time 0 (blood culture), and day 2- 3 and day 30: sepsis score.

4.5.3. Inflammation, sepsis mediators and biomarkers. - The following biomarkers will be determined during patient enrollment:

- White blood cell count and differential.

- Platelet count.

- Fibrinogen.

- Prothrombin activity.

- C reactive protein.

- Procalcitonin.

- GZM A.

GZM A serum levels will be obtained in all patients during the enrollment visit, the 2-3 day and the 30 day visits (GZM A kinetics). GZM A levels will be determined by an ELISA commercial assay (Human Granzyme A ELISA development kit{HRP]; Mabtech).

GzmA gene polymorphisms, as well as other potentially associated mutations, will be screened by Whole Exome Sequencing (WES). To this aim, we will use DNA isolated from peripheral blood cells and the AmpliSeq technology kit on the Ion Torrent platform following the manufacturer's instructions. This platform is available at the Genomics Central Research Unit (CRU) at CIBA from University of Zaragoza/IIS Aragon. All kits for isolating and analyzing DNA samples are commercially available and optimized by Thermo Scientific. Bioninformatic analysis will be performed by an agreement established between Genomics CRU and Micromics SL led by Pedro Gonzalez at CRG in Barcelona.

4.5.4. Microbiological variables

- Minimum inhibitory concentrations (MIC) of the E. coli isolates retrieved from urine and blood cultures will be determined through automated microdilution panels as routinely performed by the Microbiology Laboratory of participating hospitals.

- Whole genome sequencing (WGS) of the E. coli strains isolated in blood and urine cultures. The presence of E. coli known virulence factors will be analyzed and a virulence score for each strain will be calculated (Mora-Rillo et al., 2015).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date December 31, 2020
Est. primary completion date May 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- E. coli bacteremic urinary tract infection

Exclusion Criteria:

- Immunocompromised hosts: HIV/AIDS, Neutropenia, Solid neoplasia, Hematological neoplasia, patients receiving immunosuppressive therapy

- Systemic antibiotic therapy in the 2 months preceding the bloodstream infection

- Anatomical or functional urological abnormalities that require urological procedures in the previous 2 months

Study Design


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Instituto de Investigación Sanitaria Aragón

References & Publications (2)

Arias MA, Jiménez de Bagües MP, Aguiló N, Menao S, Hervás-Stubbs S, de Martino A, Alcaraz A, Simon MM, Froelich CJ, Pardo J. Elucidating sources and roles of granzymes A and B during bacterial infection and sepsis. Cell Rep. 2014 Jul 24;8(2):420-9. doi: 1 — View Citation

García-Laorden MI, Stroo I, Terpstra S, Florquin S, Medema JP, van T Veer C, de Vos AF, van der Poll T. Expression and Function of Granzymes A and B in Escherichia coli Peritonitis and Sepsis. Mediators Inflamm. 2017;2017:4137563. doi: 10.1155/2017/413756 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Granzyme A serum levels GZM A serum concentration (GZM A serum levels) will be determined at day 0 by an ELISA commercial assay (Human Granzyme A ELISA development kit; Mabtech) day 0
Secondary gzmA polymorphisms GzmA gene polymorphisms, as well as other potentially associated mutations, will be screened by Whole Exome Sequencing (WES). To this aim, we will use DNA isolated from peripheral blood cells and the AmpliSeq technology kit on the Ion Torrent platform following the manufacturer's instructions. This platform is available at the Genomics Central Research Unit (CRU) at CIBA from University of Zaragoza/IIS Aragon. All kits for isolating and analyzing DNA samples are commercially available and optimized by Thermo Scientific. day 0
Secondary Granzyme A serum kinetics Granzyme A serum concentration will be determined at three time points: day 0, day 2-3 and day 30. GZM A serum concentration (GZM A serum levels) will be determined by an ELISA commercial assay (Human Granzyme A ELISA development kit; Mabtech) day 2-3 and day 30
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3